Data as of Jul 30, 2026 | Current Price: $54.49 | Change: −2.36%
| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 62 | Balanced risk-reward; execution risks offset by pipeline upside | 6–12M |
| SA Quality/Value Composite | C | 58 | Negative EPS (−$8.15), no dividend; trading below 52W high of $85.60; revenue decline YoY (−29.97%) | 1–3M |
| Zacks Earnings Momentum | D+ | 51 | Expected Q2 loss (−$1.97/share); COVID revenue cliff; limited near-term profitability visibility | 1–3M |
| Institutional & Smart Money Flow | B− | 72 | YTD week52 return +66.84%; renewed analyst confidence post-Arbutus settlement; FDA flu vaccine re-review (Aug 5 PDUFA) | 1–3M |
| Growth Sustainability & Moat | B | 75 | Diversified mRNA pipeline (oncology, RSV, flu); platform strength; execution risk on FDA approvals and manufacturing scale | 6–12M |
| Valuation & Safety (Pre-Penalty) | C | 60 | Market cap $21.66B; no meaningful P/E (EPS negative); implied EV/Sales ~10.1x at current revisions; discounted vs. growth biotech | 1–3M |
| Penalty Overlay | C− | 45 | COVID revenue dependency decline; litigation/IP overhang (Arbutus settlement reducing risk); binary FDA outcomes; unproven oncology monetization | 6–12M |
| CONFIDENCE SCORE | C+ | 64 | Data gaps on upcoming earnings (reported Jul 31); limited visibility into pipeline phase/timeline; analyst divergence ($21–$69 range) | 1–3M |
| Volatility & Drawdown Risk | C | 59 | Beta 0.91 (below market); 52W range $22.28–$85.60 (wide spread); event-driven: FDA decisions, quarterly results; drawdown recovery slow | 6–12M |
| Crowding Risk Flag | B− | 71 | Analyst coverage moderate (12–23 analysts); divergent views; not consensus-heavy; retail interest elevated but not speculative bubble territory | 6–12M |
Moderna trades within a crowded biotech landscape defined by post-pandemic revenue normalization and platform diversification. Unlike pure-play vaccine companies, MRNA's mRNA platform spans oncology (immunotherapy), infectious disease (flu, RSV, COVID), and rare genetic disorder therapeutics. Current trading reflects the market's skepticism on near-term profitability (−29.97% revenue YoY) offset by institutional recognition of platform optionality. Peer comparables (Regeneron, Vertex, BioNTech) command higher multiples on consistent profitability; MRNA trades at a discount reflecting execution risk and COVID cliff transition.
Q2 earnings imminent (Jul 31 filing); watch for COVID revenue trajectory, gross margin trends, and cash burn rate. FDA PDUFA decision on mRNA-1010 flu vaccine (Aug 5) is binary catalyst. If approved, upside inflection to $60–70 range; if delayed/rejected, downside to $45–48. Near-term momentum positive on settlement news, but execution risk remains elevated.
Platform diversification narrative consolidates if FDA approvals materialize and early oncology/RSV data support market claims. Revenue stabilization expected ~$2.1–2.5B annually (vs. LIVE_DATA TTM baseline insufficient). Gross margin recovery through manufacturing optimization (per bulls: +10% over 3 years) could drive EBITDA inflection by late 2027. Institutional target price consensus ($43.37 mean, per S&P Global) implies modest downside risk at current $54.49, but analyst range wide ($21–$69) reflects execution uncertainty.
According to 23 analysts polled by S&P Global, Moderna has a consensus price target of $43.37 , representing a −20.36% discount to the current price of $54.49. The forecast range spans from a low of $21 (−61.45%) to a high of $69 (+26.66%) , reflecting substantial analyst divergence on pipeline execution and valuation reset. Analysts have shifted price targets higher by approximately $5, incorporating the Arbutus settlement, FDA's reconsideration of the mRNA-1010 flu vaccine (with an August 5 PDUFA date), and updated pipeline assumptions .
MRNA Systematic Research
Moderna Inc presents a distinctive profile as a biotechnology company transitioning from pandemic-era revenue concentration, with systematic screening highlighting significant operational stress alongside robust balance sheet metrics. Trading at $54.82 with a market capitalization of $21.8 billion, the company exhibits a price-to-sales ratio of 9.78 while generating negative profitability across all standard measures, including ROE of -36.73% and operating margin of -153.35%.
The fundamental data reveals several contrasting dynamics:
- Liquidity strength: The current ratio of 3.29 and minimal debt-to-equity of 0.07 indicate substantial financial flexibility to navigate the current revenue contraction phase, with book value per share at $21.95 supporting a price-to-book of 1.33.
- Revenue reset: Year-over-year revenue declined 29.97%, reflecting the expected normalization from COVID-19 vaccine peak demand, while gross margin of 35.01% demonstrates underlying product economics despite volume challenges.
- Loss per share: Trailing twelve-month EPS of -$8.15 underscores the company's investment-intensive phase as research and development expenses significantly exceed current commercial revenue generation.
Risk factors include the operating margin of -153.35%, which flags substantial cash consumption relative to revenue, and the 52-week price volatility between $22.28 and $85.60 reflecting market uncertainty around pipeline execution. The beta of 0.89 suggests relatively moderate systematic risk compared to broader market movements.
Positioned against peers including NTRA, BIIB, and ALNY, Moderna's valuation multiple appears elevated given current negative profitability metrics, though the balance sheet composition provides differentiation through minimal leverage and strong working capital positioning for ongoing clinical development activities.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.